Komagane

Researchers are studying ulcerative colitis (UC) to understand how serum leucine-rich alpha 2-glycoprotein (LRG) levels can predict histologic remission, which means healing seen under a microscope. This study aims to find the LRG level that indicates remission in UC patients by analyzing blood samples and tissue from colonoscopies. Histologic remission is defined using specific scores that assess inflammation in the colon tissue. Participants with active UC will have their serum LRG measured using an enzyme-linked immunosorbent assay. When histologic remission is predicted, patients will undergo a colonoscopy with tissue sampling for histological examination, regardless of their symptoms or LRG levels. Researchers will use clinical scores and endoscopic findings alongside histology to evaluate disease activity. During the study, patients will be monitored with blood tests for LRG and clinical assessments using the partial Mayo score and Mayo endoscopic subscore. The main outcome measured is histologic remission within one week. The diagnostic ability of serum LRG to predict this remission will be analyzed using statistical methods. The study includes adults aged 20 to 90 years with active UC and involves no exclusion criteria.

Researchers are studying the bleeding rates after esophagogastroduodenoscopy (EGD) and colonoscopy in patients who continue taking various antithrombotic drugs. The study focuses on both immediate bleeding, defined as bleeding lasting more than 30 seconds requiring hemostatic clipping, and delayed bleeding that occurs within two weeks after the procedure and requires endoscopic treatment. The study also evaluates the rate of injured submucosal arteries seen in the tissue samples when bleeding occurs. Participants undergo procedures including biopsy, cold or hot snare polypectomy, or endoscopic mucosal resection (EMR) during their EGD or colonoscopy. Prophylactic clipping is not performed after biopsy or polypectomy in this study. The study observes bleeding events that require treatment during or after these procedures. Throughout the study, researchers monitor for bleeding that needs hemostatic intervention and examine excised tissue samples to assess artery injury. The main outcome measured is the rate of delayed bleeding over a 10-year period. Participants range in age from 20 to 90 years and include all genders.

Researchers are conducting a randomized trial to compare the removal ability of the Vortic Catch V basket catheter with an ordinary basket catheter for removing common bile duct stones that are 10 mm or larger. This study aims to evaluate which device is more effective in clearing these stones following a specific dilation procedure. The treatment involves removing bile duct stones using either the Vortic Catch V basket catheter or the ordinary basket catheter. Both methods are performed after endoscopic papillary large balloon dilation (EPLBD), which helps to open the bile duct for stone removal. Participants will be randomly assigned to one of these two device groups during the procedure. Participants will be assessed based on the percentage of stones cleared and the procedure time. Eligibility includes patients suspected or known to have common bile duct stones of 10 mm or greater who have undergone EPLBD. Researchers will monitor for safety concerns such as infections or bleeding issues. The study focuses on the effectiveness of these two devices in removing stones during the procedure.

Researchers are investigating the link between serum leucine-rich alpha-2 glycoprotein (LRG) levels and disease activity in patients suspected of having ulcerative colitis (UC) or Crohn's disease (CD). The study aims to see if LRG can serve as a marker to predict UC or CD activity by comparing it with clinical and endoscopic assessments. Patients suspected of these conditions are being evaluated using established disease activity scores and endoscopic findings. Participants diagnosed with possible UC or CD based on various clinical, endoscopic, radiological, and histological criteria provide serum samples. These samples and colonoscopy with histology are collected within 7 days for measurement of LRG levels and disease activity. UC disease activity is assessed using the Mayo score and Mayo endoscopy score, while CD activity is evaluated with the Crohn's disease activity index (CDAI). Throughout the study, researchers review clinical records to obtain disease activity scores and monitor serum LRG levels over one year. The main outcome measured is the serum LRG level after one year, which is compared to endoscopic activity. This monitoring helps determine if LRG levels correspond with the severity or activity of UC or CD in the participants.

This research aims to evaluate the effectiveness and safety of a new oral medication called Etrasimod in elderly patients who have active ulcerative colitis. The study focuses on observing the clinical course, any side effects, and changes seen in biopsy samples after treatment with Etrasimod. The main goal is to measure how many patients reach clinical remission within 4 weeks, defined by a Clinical Activity Index score below 4. Participants receive 2 mg of Etrasimod orally every day as part of the treatment. Eligible patients are identified during routine clinical care, and those who agree to participate provide written informed consent. The study collects and analyzes data on patients' clinical progress, adverse events, and findings from endoscopic examinations and biopsies throughout the treatment period. During the study, researchers closely monitor participants for safety and effectiveness by tracking clinical symptoms, endoscopic findings, and histopathological changes in tissue samples. The primary outcome is the remission rate at 4 weeks. The total study duration and additional follow-up details are not specified. This prospective approach allows researchers to gather comprehensive information about Etrasimod's impact in this patient group.

Researchers are evaluating the effects of the traditional Japanese medicine Keishi-ka-shakuyaku-daio-to (TJ-134) compared with lactomin in patients with symptomatic pneumatosis cystoides intestinalis (PCI). This condition is identified by characteristic cysts in the colon, and the study aims to assess changes in abdominal symptoms and CT findings over the treatment period. Participants are randomly assigned to receive either TJ-134 at a dose of 7.5 grams per day or lactomin at 3 grams per day for 8 weeks. The study uses computer-generated randomization in blocks of four to assign treatments. Both treatments are administered orally during the treatment phase. At enrollment and after 8 weeks of treatment, participants undergo evaluations of abdominal symptoms and abdominal computed tomography (CT) scans to monitor changes. The primary outcome is the change in CT findings from baseline to the end of the 8-week treatment period. This monitoring helps assess the impact of the treatments on the condition.